Deep Track Capital’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Deep Track Capital’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,259,653	Closed	-$7.88M	–	71
2023 Q1	$7.88M	Hold	4,259,653	–	–	0.32%	47
2022 Q4	$4.73M	Hold	4,259,653	–	–	0.2%	52
2022 Q3	$9.97M	Hold	4,259,653	–	–	0.46%	50
2022 Q2	$12.9M	Hold	4,259,653	–	–	0.85%	36
2022 Q1	$28.9M	Buy	4,259,653 +259,653	+6%	+$1.85M	1.85%	20
2021 Q4	$33.4M	Buy	+4,000,000	New	+$33M	2.36%	17

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Deep Track Capital's JNCE Position: Q2 2023 in Review

Deep Track Capital sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 4,259,653 shares — an estimated $7.88M sold.

Deep Track Capital first reported a position in JNCE in Q4 2021 and held it in 6 quarters. The position peaked at $33.4M in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Deep Track Capital reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Deep Track Capital sold 4,259,653 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $7.88M.
Deep Track Capital first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Deep Track Capital's Jounce Therapeutics, Inc. Common Stock position peaked at $33.4M in Q4 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Deep Track Capital's 13F filing for Q2 2023, filed 14 Aug 2023.